I also see a trend here. Conservative, not a hockey stick, but rather consistent
tumor reduction, and longevity in an increasingly wide range of cancers.
No trial is perfect, and this one included some extremely sick patients. I am willing to give Bavituximab the benefit of the doubt. I think we are still in a ball game, and even though this trial was a single, we still have another man on base.
News 
Market Data 
Discover 
AI
